J Rheum Dis 2016; 23(1): 55-60
Published online February 29, 2016
© Korean College of Rheumatology
Correspondence to : Jin-Wuk Hur
Division of Rheumatology, Department of Internal Medicine, Eulji General Hospital, Eulji University College of
Medicine, 68 Hangeulbiseok-ro, Nowon-gu, Seoul 01830, Korea. E-mail: rheumatism@eulji.ac.kr
Tocilizumab, a humanized monoclonal antibody against the interleukin-6 receptor, is therapeutically effective in patients diagnosed with rheumatoid arthritis (RA) compared with placebo. However patients treated with tocilizumab are at increased risk of several adverse effects including anaphylaxis and serious infections that may lead to hospitalization or death. Therefore, the risks and benefits of treatment with tocilizumab should be considered carefully and close monitoring of patients for development of signs and symptoms of side effects is required during and after treatment. Here, we report on a rare case of anaphylaxis and severe sepsis caused by cellulitis in a patient with RA after tocilizumab treatment. (J Rheum Dis 2016;23:55-60)
Keywords Tocilizumab, Anaphylaxis, Cellulitis, Sepsis
J Rheum Dis 2016; 23(1): 55-60
Published online February 29, 2016
Copyright © Korean College of Rheumatology.
Min Seok Yoo, Ji Sang Park, Yoon Suk Park, Hye Won Kim, Jin-Wuk Hur
Division of Rheumatology, Department of Internal Medicine, Eulji General Hospital, Eulji University College of Medicine, Seoul, Korea
Correspondence to:Jin-Wuk Hur
Division of Rheumatology, Department of Internal Medicine, Eulji General Hospital, Eulji University College of
Medicine, 68 Hangeulbiseok-ro, Nowon-gu, Seoul 01830, Korea. E-mail: rheumatism@eulji.ac.kr
Tocilizumab, a humanized monoclonal antibody against the interleukin-6 receptor, is therapeutically effective in patients diagnosed with rheumatoid arthritis (RA) compared with placebo. However patients treated with tocilizumab are at increased risk of several adverse effects including anaphylaxis and serious infections that may lead to hospitalization or death. Therefore, the risks and benefits of treatment with tocilizumab should be considered carefully and close monitoring of patients for development of signs and symptoms of side effects is required during and after treatment. Here, we report on a rare case of anaphylaxis and severe sepsis caused by cellulitis in a patient with RA after tocilizumab treatment. (J Rheum Dis 2016;23:55-60)
Keywords: Tocilizumab, Anaphylaxis, Cellulitis, Sepsis
Jung Gon Kim, M.D., M.S., Bon San Koo, M.D., Ph.D., Joo-Hyun Lee, M.D., Ph.D., Bo Young Yoon, M.D., Ph.D.
J Rheum Dis 2024; 31(4): 212-222Ju Ho Lee, M.D., You-Jung Ha, M.D., Ph.D., Eun Ha Kang, M.D., Ph.D., Sung Hae Chang, M.D., Yun Jong Lee, M.D., Ph.D.
J Rheum Dis 2022; 29(2): 123-128Jina Yeo, M.D., Han Joo Baek, M.D., Ph.D., Yeong Wook Song, M.D., Ph.D., Eun Young Lee, M.D., Ph.D.
J Rheum Dis 2022; 29(2): 89-97